Chronic Hepatitis B
Conditions
Brief summary
The objectives are to demonstrate that entecavir has antiviral activity undetectable HBV DNA measured, the Roche AmplicorTM PCR at Week 48, and to assess the safety and the pharmacokinetic of entecavir in Japanese patients with hepatitis B who have an incomplete response to current lamivudine therapy
Interventions
DRUGEntecavir
Tablet, P.O., 0.5 mg or 1mg, once daily, 52 weeks
Sponsors
Bristol-Myers Squibb
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Documentation of chronic hepatitis B infection by ALL of the following: 1. Positive for HBsAg OR, negative for IgM core antibody and confirmation of chronic hepatitis B on liver biopsy 2. Patient who have received lamivudine therapy for 24 weeks or more, or patient who have documented YMDD mutation or other lamivudine-resistant mutation while on lamivudine 3. Documented HBV Viremia ≥ 10\*5: copies/mL * ALT in the range of 1.3 to 10 x ULN * Subjects must have well-compensated liver disease a) value
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the safety (the incidence of clinical adverse events and discontinuations due to adverse events) | Week 52 (end of dosing) plus 5 days |
| To assess the proportion of subjects with reduction in HBV DNA by ≥ 2 log10 or to undetectable level (< 400 copies/mL) | at Week 48 |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of subjects HBeAg-positive at baseline who have loss of HBeAg from serum at Week 48 | Week 48 |
| Proportion of subjects HBeAg-positive at baseline who achieve seroconversion (loss of HBeAg and appearance of HBeAb) at Week 48 | Week 48 |
| Proportion of subjects with abnormal ALT at baseline who achieve normalization of serum ALT (<1.25 x ULN) at Week 48 | Week 48 |
| Proportion of subjects HBeAg-positive at baseline who have complete response (undetectable HBV DNA levels by PCR assay, negative for HBeAg and normal serum ALT) at Week 48 | Week 48 |
| Proportion of subjects HBeAg-negative at baseline who have undetectable HBV DNA levels by PCR assay, remain negative for HBeAg and normal serum ALT at Week 48 | Week 48 |
| Proportion of subjects w/ histological improvement in liver (improvement in necroinflammatory score (≥2 points decrease, Knodell HAI3 score) & no worsening of fibrosis (≥1 point increase, Knodell fibrosis score) at Wk 48 liver biopsy compared to baseline | Baseline, Week 48 |
| Mean change from baseline in the log*10* HBV DNA measured by PCR assay for each entecavir dose (0.5 and 1 mg) at Week 48 | Baseline, Week 48 |
| Relationship between HBV isolates (genotypes A,B,C, etc.) at baseline and antiviral activity | Week 48, or at end of dosing (up to Week 52) |
| Incidence of resistance mutations of HBV isolates in subjects who have a rise in HBV DNA (by ≥1 log above the nadir for that subject) while on study drug. | Week 48, or at end of dosing (up to Week 52) |
| Mutation of HBV DNA polymerase at Week 48 from baseline | Baseline, Week 48 |
| Plasma concentrations of entecavir at selected time points during the treatment period | pre-dosing, Week 2 or 4, Week 12, Week 24 and Week 36 |
| Population pharmacokinetic assessment of entecavir developed from concentration-time data obtained from healthy subjects | pre-dosing, Week 2 or 4, Week 12, Week 24 and Week 36 |
| Changes in liver histology as assessed by the New Inuyama Classification for histological assessment of chronic hepatitis | Week 52 |
| Proportion of subjects who achieve undetectable HBV DNA (<400 copies/mL) by PCR assay at Week 48 | Week 48 |
Countries
Japan
Outcome results
None listed